Orca Bio

Senior Safety Scientist

Remote

Not SpecifiedCompensation
Junior (1 to 2 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
BiotechnologyIndustries

Requirements

Candidates should possess an advanced degree in a biologic, medical, clinical, or nursing field, such as a Pharmacist/PharmD, RN/NP, or PhD. They must have a minimum of 3-5 years of experience in the biotechnology or pharmaceutical industry, with at least 3 years dedicated to drug safety, safety science, and risk management. Knowledge of US and EU pre- and post-marketing pharmacovigilance requirements is essential, along with proficiency in preparing safety regulatory documents including DSURs, PSURs, and RMPs.

Responsibilities

The Senior Safety Scientist will support signal detection, evaluation, and management through aggregate data analysis and case-level reviews, creating presentations for assigned programs or studies. They will assist in developing risk management strategies for both pre- and post-marketed programs, including contributing to RMPs, evaluating risk minimization activities, and responding to regulatory safety requests. The role involves reviewing adverse events/serious adverse events from clinical trials, providing input on TFLs, listings, and biometrics outputs, and leading the preparation of periodic safety reports (DSUR, PSUR, PBRER) in accordance with regulatory requirements. Furthermore, the Senior Safety Scientist will support safety governance activities, conduct literature reviews, contribute to regulatory filings (CSRs, IBs, labeling), support inspection preparedness, and stay updated on regulatory changes and SOPs.

Skills

Pharmacovigilance
Safety Data Analysis
Regulatory Documentation (DSURs, PSURs, RMPs)
Risk Management
Signal Detection
Clinical Trial Safety Review
Risk/Benefit Analysis
Regulatory Compliance
Clinical Development

Orca Bio

Develops and commercializes cell therapies

About Orca Bio

Orca Bio operates in the biotechnology sector, specifically focusing on cell therapies that utilize the body's own cells to treat diseases. The company works to enhance these therapies, aiming to make them safer and more effective for patients. Orca Bio's products are primarily used by healthcare providers who administer these therapies to patients as part of their treatment plans. Unlike many competitors, Orca Bio emphasizes a strong team culture and values communication with stakeholders, keeping them informed about the company's progress and developments. The goal of Orca Bio is to improve patient outcomes through advanced cell therapies, addressing conditions that currently have limited treatment options.

Key Metrics

Menlo Park, CaliforniaHeadquarters
2016Year Founded
$186.8MTotal Funding
SERIES_DCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
401(k) Retirement Plan
Parental Leave

Risks

Emerging competition from BlueRock Therapeutics in stem cell therapies.
Aspen Neuroscience's advancements in personalized stem cell therapies pose a threat.
Competitors' focus on iPSC-derived therapies may overshadow Orca Bio's offerings.

Differentiation

Orca Bio focuses on high-precision cell therapies for cancer and autoimmune diseases.
Their lead product, Orca-T, shows promising relapse-free survival rates in clinical trials.
Orca Bio's therapies aim to replace diseased blood and immune systems with healthy ones.

Upsides

Orca-T demonstrated 87% relapse-free survival in a Phase 1b/2 trial.
FDA's expedited approval pathways could accelerate Orca Bio's market entry.
Advancements in gene editing enhance the efficacy of Orca Bio's cell therapies.

Land your dream remote job 3x faster with AI